Francesca T Aweeka

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc The metabolic effects of lopinavir/ritonavir in HIV-negative men
    Grace A Lee
    Metabolism Section 111F, San Francisco Department of Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    AIDS 18:641-9. 2004
  2. pmc A Modified Method for Determination of Lumefantrine in Human Plasma by HPLC-UV and Combination of Protein Precipitation and Solid-Phase Extraction: Application to a Pharmacokinetic Study
    Liusheng Huang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA
    Anal Chem Insights 5:15-23. 2010
  3. ncbi request reprint Clinical pharmacology of artemisinin-based combination therapies
    Polina I German
    Drug Research Unit, University of California, San Francisco, California 94143 0622, USA
    Clin Pharmacokinet 47:91-102. 2008
  4. ncbi request reprint Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team
    F T Aweeka
    Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
    HIV Med 8:288-94. 2007
  5. pmc Lopinavir protein binding in HIV-1-infected pregnant women
    F T Aweeka
    Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
    HIV Med 11:232-8. 2010
  6. ncbi request reprint The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine
    Francesca T Aweeka
    Drug Research Unit, University of California, San Francisco, California 94143 0622, USA
    AIDS 20:1833-41. 2006
  7. doi request reprint The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers
    Vivian Y Pao
    Department of Medicine, University of California, CA, USA
    AIDS 24:265-70. 2010
  8. ncbi request reprint Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial
    Donald I Abrams
    University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
    Ann Intern Med 139:258-66. 2003
  9. pmc Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:310-6. 2012
  10. pmc Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers
    Steven A Taylor
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 55:361-4. 2010

Detail Information

Publications33

  1. pmc The metabolic effects of lopinavir/ritonavir in HIV-negative men
    Grace A Lee
    Metabolism Section 111F, San Francisco Department of Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    AIDS 18:641-9. 2004
    ..Therefore, we tested the effects of the PI combination lopinavir and ritonavir on glucose and lipid metabolism in HIV-negative subjects...
  2. pmc A Modified Method for Determination of Lumefantrine in Human Plasma by HPLC-UV and Combination of Protein Precipitation and Solid-Phase Extraction: Application to a Pharmacokinetic Study
    Liusheng Huang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA
    Anal Chem Insights 5:15-23. 2010
    ..This method was successfully applied to a pharmacokinetic interaction study between a first-line antimalarial combination (artemether-lumefantrine) and antiretroviral therapy...
  3. ncbi request reprint Clinical pharmacology of artemisinin-based combination therapies
    Polina I German
    Drug Research Unit, University of California, San Francisco, California 94143 0622, USA
    Clin Pharmacokinet 47:91-102. 2008
    ..Alterations in antimalarial drug plasma concentrations may lead to either suboptimal efficacy or drug toxicity and may compromise treatment...
  4. ncbi request reprint Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team
    F T Aweeka
    Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
    HIV Med 8:288-94. 2007
    ..We sought to investigate the potential antagonism between RBV and ZDV by evaluating the impact of RBV on the formation of intracellular ZDV triphosphate (TP) in HIV-infected patients receiving ZDV who were treated for HCV infection...
  5. pmc Lopinavir protein binding in HIV-1-infected pregnant women
    F T Aweeka
    Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
    HIV Med 11:232-8. 2010
    ..We report lopinavir (LPV) PB during third trimester (antepartum, AP) compared to > or =1.7 weeks postpartum (PP) to determine if FU changes compensate for reduced total concentrations reported previously...
  6. ncbi request reprint The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine
    Francesca T Aweeka
    Drug Research Unit, University of California, San Francisco, California 94143 0622, USA
    AIDS 20:1833-41. 2006
    ..This study evaluated the impact of female sex and contraceptive therapy on zidovudine plasma and intracellular pharmacokinetics and the impact of contraceptive therapy on HIV viral load...
  7. doi request reprint The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers
    Vivian Y Pao
    Department of Medicine, University of California, CA, USA
    AIDS 24:265-70. 2010
    ..We studied the effects of the protease inhibitor combination lopinavir and ritonavir on insulin secretion, insulin sensitivity, and lipid metabolism in HIV-negative persons...
  8. ncbi request reprint Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial
    Donald I Abrams
    University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
    Ann Intern Med 139:258-66. 2003
    ..Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways)...
  9. pmc Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:310-6. 2012
    ..A study in healthy volunteers was completed to address the concern that EFV impacts AL pharmacokinetics (PKs)...
  10. pmc Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers
    Steven A Taylor
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 55:361-4. 2010
    ..Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on glucose metabolism have not been described in the absence of another PI...
  11. pmc Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma
    Liusheng Huang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA
    J Pharm Biomed Anal 50:959-65. 2009
    ..The calibration range was 2-200 ng/mL. The recovery was 73-81% for artemether and 90-99% for dihydroartemisinin. The validated method was applied to analysis of clinical samples with results in good agreement with an existing method...
  12. pmc Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA
    Bioanalysis 4:157-66. 2012
    ..To support pediatric study, a method to determine lumefantrine (LF) with small sample volume is needed. Matrix effect (ME) is a daunting issue in LF quantification in human plasma with LC-MS/MS...
  13. ncbi request reprint Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS
    Jingduan Chi
    Department of Clinical Pharmacy, Drug Research Unit, School of Pharmacy, University of California, San Francisco, CA 94143, USA
    J Pharm Biomed Anal 30:675-84. 2002
    ..Mean inter- and intra-assay coefficients of variation (CVs) over the ranges of the standard curves were less than 10%. The overall recovery of NFV, IDV, RTV, SQV and APV were 88.4, 91.4, 92.2, 88.9 and 87.6%, respectively...
  14. ncbi request reprint Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women
    Bradley W Kosel
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, 94143, USA
    AIDS 17:1195-9. 2003
    ..Increased cytochrome P450 activity may affect the disposition of PI and decrease drug exposure...
  15. pmc Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma
    Liusheng Huang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94110, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 877:285-90. 2009
    ..The recovery was over 90% and matrix effect was negligible. The method is simple and fast, which is advantageous in respect to instability of isoniazid in human plasma and loss on reconstitution due to its low molecular weight...
  16. doi request reprint Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers
    Polina German
    Department of Clinical Pharmacy, Drug Research, University of California, School of Medicine, San Francisco, CA 94143 0622, USA
    J Acquir Immune Defic Syndr 51:424-9. 2009
    ....
  17. ncbi request reprint Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships
    Dolors Soy
    Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, Calif, USA
    Clin Pharmacol Ther 74:569-80. 2003
    ..Our objective was to describe the population pharmacokinetics and pharmacodynamics of enfuvirtide acting on viral ribonucleic acid in children with human immunodeficiency virus 1...
  18. ncbi request reprint The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir
    Bradley W Kosel
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94110, USA
    AIDS 16:543-50. 2002
    ..We present pharmacokinetic data from a randomized placebo-controlled study designed to evaluate the metabolic effects of smoked marijuana and dronabinol in HIV-infected patients receiving indinavir (IDV) or nelfinavir (NFV)...
  19. ncbi request reprint Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377
    Leslie Carstensen Floren
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA
    Pediatrics 112:e220-7. 2003
    ....
  20. pmc Nevirapine inhibits the anti-HIV activity of CD8+ cells
    Lianxing Liu
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 1270, USA
    J Acquir Immune Defic Syndr 63:184-8. 2013
    ..These studies indicate that nevirapine and probably zidovudine can inhibit the anti-HIV activity of CD8(+) cells and thus could influence the effectiveness of antiretroviral therapy...
  21. pmc Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women
    Betty J Dong
    University of California, San Francisco, 94143 0622, USA
    AIDS 26:833-41. 2012
    ..To estimate nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa...
  22. ncbi request reprint An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma
    Jingduan Chi
    Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143, USA
    J Pharm Biomed Anal 31:953-9. 2003
    ..Mean inter- and intra-assay coefficients of variation (CVs) over the ranges of the two standard curves were less than 10%. The overall recovery of NVP was 92.4%...
  23. pmc Interactions between alcohol and the HIV entry inhibitor Maraviroc
    Valerie A Gruber
    Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA
    J Int Assoc Provid AIDS Care 12:375-7. 2013
    ..The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics...
  24. ncbi request reprint Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations
    F T Aweeka
    Department of Clinical Pharmacy, University of California, San Francisco 94143 0622, USA
    J Acquir Immune Defic Syndr Hum Retrovirol 20:350-7. 1999
    ..To develop specific dosage guidelines, information on the disposition of this compound in patients with varying degrees of renal function and those requiring dialysis is essential...
  25. pmc Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, CA 94110, USA
    Bioanalysis 5:1501-6. 2013
    ..Numerous methods have been reported for the determination of artemether (ARM) and its metabolite dihydroartemisinin (DHA) in plasma. However, stability issues in patient plasma have not received enough attention...
  26. ncbi request reprint Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization
    Claudia Herforth
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Eur J Pharm Sci 15:185-95. 2002
    ..0 ng/ml, permitting analysis of samples with total concentrations of nelfinavir in plasma that are > or = 400 ng/ml. This developed method proves reproducible and sensitive and its application to patient plasma samples is also reported...
  27. pmc Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study
    Mustafa A Noor
    Department of Medicine, University of California, Berkeley, California, USA
    AIDS 16:F1-8. 2002
    ..We hypothesized that a single dose of the PI indinavir resulting in therapeutic plasma concentrations would acutely decrease insulin-stimulated glucose disposal in healthy human volunteers...
  28. pmc Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco UCSF, San Francisco, CA 94143 0874, USA
    Clin Infect Dis 56:598-605. 2013
    ..We estimated population-based HIV RNA levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up...
  29. ncbi request reprint Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions
    T Motoya
    Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, CA 94143 0622, USA
    HIV Med 7:122-8. 2006
    ....
  30. ncbi request reprint An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma
    A L Jayewardene
    Department of Clinical Pharmacy, Drug Research Unit, School of Pharmacy, University of California, San Francisco, CA 94143-0622, USA
    J Pharm Biomed Anal 25:309-17. 2001
    ..The robust nature of this assay has been further verified during routine use over several months involving multiple analysts...
  31. ncbi request reprint A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS
    J Chi
    Department of Clinical Pharmacy, Drug Research Unit, School of Pharmacy, University of California, San Francisco, CA 94143-0622, USA
    J Pharm Biomed Anal 26:829-36. 2001
    ..The calibration curve was linear over the range 0.8-800 ng/ml. Mean inter- and intra-assay coefficients of variation (CVs) over the range of the standard curve were less than 10%. The overall recovery of TTP was 103.5%...
  32. ncbi request reprint Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz
    Polina German
    Clin Infect Dis 44:889-91. 2007
  33. ncbi request reprint Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267
    David A Wohl
    Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    J Infect Dis 185:1359-63. 2002
    ..Previous suggestions of autoinduction of drug metabolism were not confirmed by this study. At the doses studied, thalidomide was tolerated well and had linear pharmacokinetics...